Format

Send to

Choose Destination
Haematologica. 2018 Mar;103(3):e130. doi: 10.3324/haematol.2017.186932.

Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Author information

1
Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland sophie.voruz@chuv.ch.
2
Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.
3
Department of Oncology, University Hospital of Lausanne, Switzerland.
4
Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland.
PMID:
29491129
PMCID:
PMC5830398
DOI:
10.3324/haematol.2017.186932
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center